Swept Source OCT Imaging With the DREAM VG-OCT

Glaucoma Clinical Trial

Official title:

Swept Source OCT Imaging With the DREAM VG-OCT

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05876689
• Other study ID #: 70411
• Status: Recruiting
• Start date: October 9, 2023
• Est. completion date: December 2024

Study information

• Verified date: November 2023
• Source: Stanford University
• Contact: Study Team
• Phone: 6504975942
• Email: zacwenn[@]stanford.edu
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The Intalight Dream OCT is the first combo anterior plus posterior device to perform both OCT and OCT-A at depth of 16mm. This is especially useful in patient who are very nearsighted as it allows us to image all in one frame. The intention of this study is to see how the images differ on the same patients when compared to the Cirrus OCT and to test for the repeatability of the images on a single day.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 50
• Est. completion date: December 2024
• Est. primary completion date: December 2024
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Age greater than or equal to 18
• Myopes with a current or previously documented spherical equivalent refraction < -4D
• At least half of the subjects should have had at least one Cirrus OCT RNFL and macula performed as well as a Humphrey visual field performed in those with OCT abnormalities

Exclusion Criteria:

• Unable to comply with study imaging
• unclear ocular media
• Participant has, in the opinion of the investigator, any physical or mental condition that would affect the participation in the study or may interfere with the study procedures, evaluations and outcome assessments.

Related Conditions & MeSH terms

• Eye Diseases
• Glaucoma
• Myopia

Intervention

Device:
• DREAM OCT
Swept Source OCT (similar to Zeiss Plex Elite)

Locations

Country	Name	City	State
United States	Byers Eye Institute	Palo Alto	California

Sponsors (1)

Lead Sponsor	Collaborator
Robert T. Chang, MD

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Assessing difference in intraocular structures	Assessing the performance of the DREAM VG OCT scan patterns in high myopes including glaucomatous eyes to see if there are differences in the lamina cribrosa structure when compared to patients previous Cirrus OCTs.	Baseline
Primary	Assessing difference in intraocular vascular structures	Assessing differences in vascular density in areas with presumed myopic-related field defects vs. low tension glaucoma perimetric disease	Baseline
Secondary	Assessing repeatability of scans	Analyze the repeatability of quantitative RNFL and GCC parameters.	Baseline